C
37.45
-1.22 (-3.15%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Corcept Therapeutics Incorporat | Bearish | Bullish |
Stockmoo Score
-0.7
|
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 78.00 (Canaccord Genuity, 108.28%) | Buy |
| Median | 55.00 (46.86%) | |
| Low | 38.00 (Piper Sandler, 1.47%) | Buy |
| Average | 56.50 (50.87%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 34.88 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 31 Jul 2024 | 78.00 (108.28%) | Buy | 38.67 |
| 30 Jul 2024 | 38.00 (1.47%) | Buy | 36.12 | |
| HC Wainwright & Co. | 30 Jul 2024 | 45.00 (20.16%) | Buy | 36.12 |
| Piper Sandler | 30 Jul 2024 | 38.00 (1.47%) | Buy | 36.12 |
| 01 Jul 2024 | 35.00 (-6.54%) | Buy | 32.67 | |
| Truist Securities | 17 Jun 2024 | 65.00 (73.56%) | Buy | 28.59 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| GUYER WILLIAM | - | 34.26 | -10,243 | -350,925 |
| LYON JOSEPH DOUGLAS | 34.26 | 34.26 | 615 | 21,070 |
| MADUCK SEAN | 34.26 | 34.26 | 684 | 23,434 |
| MOKARI ATABAK | 34.26 | 34.26 | 657 | 22,509 |
| ROBB GARY CHARLES | 34.26 | 34.26 | 752 | 25,764 |
| Aggregate Net Quantity | -7,535 | |||
| Aggregate Net Value ($) | -258,149 | |||
| Aggregate Avg. Buy ($) | 34.26 | |||
| Aggregate Avg. Sell ($) | 34.26 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| ROBB GARY CHARLES | Officer | 03 Sep 2024 | Disposed (-) | 254 | 34.26 | 8,702 |
| ROBB GARY CHARLES | Officer | 03 Sep 2024 | Acquired (+) | 1,006 | 34.26 | 34,466 |
| GUYER WILLIAM | Officer | 03 Sep 2024 | Automatic sell (-) | 10,000 | 34.26 | 342,600 |
| GUYER WILLIAM | Officer | 03 Sep 2024 | Disposed (-) | 243 | 34.26 | 8,325 |
| GUYER WILLIAM | Officer | 03 Sep 2024 | Option execute | 10,000 | - | - |
| MADUCK SEAN | Officer | 03 Sep 2024 | Disposed (-) | 232 | 34.26 | 7,948 |
| MADUCK SEAN | Officer | 03 Sep 2024 | Acquired (+) | 916 | 34.26 | 31,382 |
| MOKARI ATABAK | Officer | 03 Sep 2024 | Disposed (-) | 143 | 34.26 | 4,899 |
| MOKARI ATABAK | Officer | 03 Sep 2024 | Acquired (+) | 800 | 34.26 | 27,408 |
| LYON JOSEPH DOUGLAS | Officer | 03 Sep 2024 | Disposed (-) | 129 | 34.26 | 4,420 |
| LYON JOSEPH DOUGLAS | Officer | 03 Sep 2024 | Acquired (+) | 744 | 34.26 | 25,489 |
| Show more | ||||||
| Date | Type | Details |
|---|---|---|
| 29 Jul 2024 | Announcement | Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update |
| 22 Jul 2024 | Announcement | Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call |
| 24 Jun 2024 | Announcement | Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |